CCR7 and COVID-19: Compared to hospitalized COVID-19 patients during acute disease, patients at 3–6 months of convalescence showed higher proportions of CD4+ and CD8+ CCR7–CD45RA+ effector T cells and reduced expression of the proliferation marker Ki-67.